SCHEMBL18044865

SCHEMBL18044865

NC(=O)c1cc(S(=O)(=O)C2CNCCO2)sc1NC(=O)c1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ CHEK1 O14757 2/20 0.40
▸ CFTR P13569 3/20 0.40
▸ SLC6A3 Q01959 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ CDK2AP1 O14519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044883 0.90 CFTR (0.40) CHEK1CFTRMAPTALDH1A1CDK2AP1
SCHEMBL18044862 0.89 CFTR (0.39) CHEK1CFTRMEN1KMT2ACDK2AP1
SCHEMBL18044866 0.87 CFTR (0.36) CHEK1CFTRSLC6A3KCNH2TAAR1
SCHEMBL18044900 0.86 CFTR (0.40) CHEK1CFTR
SCHEMBL18044877 0.85 CFTR (0.38) CHEK1CFTRSLC6A3KCNH2TAAR1
SCHEMBL18044863 0.85 CFTR (0.36) CHEK1CFTRSLC6A3KCNH2TAAR1
SCHEMBL18044875 0.84 SLC6A3 (0.51) CHEK1CFTRSLC6A3KCNH2TAAR1
SCHEMBL18044889 0.84 CFTR (0.38) CHEK1CFTRCDK2AP1
SCHEMBL18044891 0.84 CFTR (0.39) CHEK1CFTRSLC6A3KCNH2TAAR1
SCHEMBL18044890 0.83 CFTR (0.40) CHEK1CFTRSLC6A3KCNH2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867806-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2018-01-16 — — US disclosed
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC3, ABCC5 IKBKB 2008/4885FLT3 3103/4885CHEK1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback